Advanced Innovative Partners (AIP) is a clinical-stage biotechnology company with a highly skilled team that has developed patented platform technologies for the treatment and clinical management of hard-to-cure conditions in
oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. AIP's focus on precision medicine and personalized treatments allows for more effective targeting of breast, lung cancers and other solid tumors, while minimizing harm to healthy cells and reducing or
eliminating the risk of side effects.

AIP has the capability and experience to obtain regulatory agency approvals, with several drugs in various stages of development, from early discovery to clinical stage. This makes us a highly attractive investment opportunity, especially considering the substantial capital invested and transactions in therapidly growing radiopharmaceutical industry.